01—Abstract
Summary
Summary of the 8-K filed May 7, 2020. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an 8-K on May 7, 2020, primarily to report its first-quarter 2020 financial results and disclose a CFO separation agreement.
The press release detailing the Q1 2020 results, furnished as Exhibit 99.1, is the main focus for investors interested in operational performance. The filing also details the executive retention and separation agreement with Chief Financial Officer, Lorence Kim, M.D., who will continue in his role until August 31, 2020, and will receive specific severance and bonus payments upon departure under defined conditions. While the 8-K itself doesn't provide the Q1 2020 financial figures, it directs investors to the accompanying press release for this crucial information.
The CFO separation agreement outlines the terms of Dr. Kim's transition, including his continued salary, severance package, and retention bonus, providing clarity on executive transitions. Investors should consult Exhibit 99.1 for detailed financial performance and Exhibit 10.1 for the specifics of the CFO's separation terms.
02—Key points
Key Highlights
- Moderna reported its Q1 2020 results of operations and financial condition via a press release (Exhibit 99.1).
- The company entered into an Executive Retention and Separation Agreement with CFO Lorence Kim, M.D.
- Dr. Kim will serve as CFO until August 31, 2020.
- The agreement outlines specific severance payments (6 months base salary) and a retention bonus (50% of target bonus) for Dr. Kim, contingent on certain conditions.
- Dr. Kim's base salary will remain at no less than $582,000 until his separation, subject to across-the-board executive salary reductions.
- Existing equity awards for Dr. Kim will continue to be governed by their original terms.
- The filing incorporates the press release and separation agreement by reference as exhibits.
03—Questions
Frequently Asked Questions
Where can I find Moderna's Q1 2020 financial results?
Moderna's Q1 2020 results are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. Investors should refer to that document for specific financial performance data.
What is the financial impact of the CFO's departure on Moderna?
The financial impact is primarily related to the severance and retention payments outlined in the separation agreement for Dr. Lorence Kim. He is entitled to a lump sum equal to six months of his base salary and a one-time cash payment equal to 50% of his annual target bonus, provided he meets the agreement's conditions. The exact financial amounts for these payments would depend on his base salary and target bonus at the time of separation.
When will the current CFO, Lorence Kim, M.D., officially leave Moderna?
Dr. Lorence Kim is expected to continue as CFO through August 31, 2020, as per the Executive Retention and Separation Agreement. His separation from employment will be on or after this date.
Are there any new financial accounting standards adopted by Moderna in this filing?
This 8-K filing does not indicate that Moderna has elected to use the extended transition period for complying with new or revised financial accounting standards. The filing itself is focused on Q1 2020 results and an executive separation, rather than changes in accounting standard adoption.
04—Continue